Fierce Pharma
AUGUST 1, 2024
Like clockwork, another lawsuit challenging the constitutionality of the Inflation Reduction Act's (IRA's) price-setting measures has been shot down in the courts. | The ruling from the New Jersey federal court marks the latest in a string of rejections as various drugmakers have taken to the courts to fight the drug pricing legislation.
MedCity News
AUGUST 1, 2024
Healthcare organizations can significantly improve their resilience against ransomware attacks by implementing proactive protection, continuous monitoring, and rapid recovery strategies. Proactive protection, continuous monitoring, and rapid recovery strategies are key. The post Nearly Every Large Healthcare Organization Uses Microsoft Active Directory: Here’s How to Secure It to Safeguard Against Escalating Ransomware Attacks appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 1, 2024
Like many other biopharma companies, Kyowa Kirin is in restructuring mode. | Kyowa Kirin is planning “a significant reduction” in its small molecule drug discovery research activities and will trim certain manufacturing roles. The company is also divesting its Chinese operations as part of a larger restructuring in the Asia-Pacific region.
MedCity News
AUGUST 1, 2024
Huma has spent 10 years perfecting its technology stack and now it wants others to build off of its expertise, says the company’s chief medical officer. The post Huma’s Evolution From Patient Monitoring Apps to Cloud Platform With AI Chops appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
AUGUST 1, 2024
Two weeks ago, Novartis CEO Vas Narasimhan referred to the initial wave of drug pricing effects tied to the Inflation Reduction Act (IRA) as “manageable.” | Novartis has filed a lawsuit against the FDA, claiming that the U.S. regulator’s approval of a generic version of Entresto is unlawful. The complaint comes a week after the FDA approved an Entresto generic from MSN Laboratories.
MedCity News
AUGUST 1, 2024
Here is a list of some of the biggest funding rounds from health tech companies that were announced in July. The post 5 Notable Health Tech Funding Announcements in July appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
AUGUST 1, 2024
A new report showed that financial margins have leveled off for both hospitals and physician groups in recent months. However, costs for drugs and labor continue to climb. The post Providers’ Finances Are Steady, But Cost Pressures Still Loom appeared first on MedCity News.
Fierce Pharma
AUGUST 1, 2024
With U.S. sales of $304 million during the second quarter, Regeneron’s high-dose version of Eylea came up just short of analyst projections. | The launch of Regeneron's Eylea HD has helped the Eylea franchise to a rebound after U.S. sales had declined in each of the previous three quarters. Additionally, Regeneron reported that its FDA decision date on its application for approval of multiple myeloma therapy linvoseltamab is likely to be delayed because of a manufacturing issue.
PharmaVoice
AUGUST 1, 2024
From an epic, alternative reality fantasy to a ‘biography of cancer,’ these six reads have stuck with pharma execs as they navigate how to lead.
Fierce Pharma
AUGUST 1, 2024
Eli Lilly, after tirzepatide's late-stage cardio win, plots regulatory filings this year esagonowsky Thu, 08/01/2024 - 09:40
Pharmaceutical Technology
AUGUST 1, 2024
The UK NICE has recommended BeiGene’s Zanubrutinib for marginal zone lymphoma (MZL) for use on the National Health Service (NHS).
Fierce Pharma
AUGUST 1, 2024
The post-pandemic period has posed serious challenges for financial forecasters at the top mRNA vaccine makers, as evidenced by Pfizer's
pharmaphorum
AUGUST 1, 2024
Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.The French pharma company – best known for its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in LimmaTech's S4V vaccine candidate, and promising undisclosed regulatory, development and sales-based milestone payments.
Fierce Pharma
AUGUST 1, 2024
Despite missing the primary endpoint in a pediatric study, Agios says it remains steadfast in working to grow the reach of its pyruvate kinase (PK) activation franchise. | The trial in PK-deficient children who receive regular transfusions didn't meet its primary endpoint based on an analysis that incorporated response data from a prior adult study.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Pharmaceutical Technology
AUGUST 1, 2024
The acquisition is expected to conclude in Q3 this year and will see Otsuka adding Jnana’s phenylketonuria therapy to its portfolio.
MedCity News
AUGUST 1, 2024
Otsuka Pharmaceutical is acquiring Jnana Therapeutics, whose lead drug is a potential treatment for the rare metabolic disorder phenylketonuria (PKU). Jnana’s drug could provide an alternative to two FDA-approved PKU medicines from BioMarin Pharmaceutical. The post Otsuka Commits $800M in M&A Deal Bringing a Phase 3-Ready Metabolic Disorder Drug appeared first on MedCity News.
pharmaphorum
AUGUST 1, 2024
Bayer files elinzanetant as a non-hormonal treatment for menopausal symptoms, with Astellas' first-to-market Veozah in its sights
Pharmaceutical Technology
AUGUST 1, 2024
Takeda has reported a revenue of Y1,208bn for Q1 FY2024, a 14.1% increase from Y1,058bn in the corresponding period of FY2023.
pharmaphorum
AUGUST 1, 2024
UK DNA/RNA sequencing specialist Oxford Nanopore raises £80m in a share issue backed with £50m from Novo Holdings
Pharmaceutical Technology
AUGUST 1, 2024
Valneva and LimmaTech have signed a deal to potentially develop the first marketed shigellosis vaccine.
PharmaTech
AUGUST 1, 2024
In this exclusive Drug Digest video interview, Felicity Thomas, Associate Editorial Director, Pharmaceutical Technology Group, interviews experts from Biosynth and the University of Maryland about biopharmaceutical drug development and manufacturing.
PharmaTimes
AUGUST 1, 2024
Combined, ovarian and breast cancer affect over 60,000 women in the UK every year
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PM360
AUGUST 1, 2024
CHICAGO – Aug. 1, 2024 – EVERSANA , a leading provider of global commercial services to the life sciences industry, today introduced TEDAVI , the pharmaceutical and life science industry’s premier content transformation hub built to streamline content production, enable personalization at scale and accelerate time-to-market for brand assets while ensuring compliance.
PharmaTimes
AUGUST 1, 2024
The collaboration aims to develop new medicines to reduce chronic kidney disease in Scotland
PharmExec
AUGUST 1, 2024
Data from the SUMMIT clinical trial demonstrated that tirzepatide lowered the risk of negative heart failure outcomes and enhanced symptoms and physical limitations when tested with three different doses.
Pharmaceutical Technology
AUGUST 1, 2024
During a session at the 2024 Alzheimer’s Association International Conference (AAIC), which concludes today, Ralph Carmona shared his experience of being diagnosed with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
European Pharmaceutical Review
AUGUST 1, 2024
A study has illustrated the development and validation steps for a digital twin “combining a physical-chemical-based mechanistic model for all unit operations with a process analytical technology (PAT) strategy” for bioprocessing. According to Hengelbrock et al. , developing and incorporating digital twins for Quality-by-Design (QbD)-based process approaches is a major challenge in modern biotechnology.
ALULA
AUGUST 1, 2024
Imagine a high-stakes business negotiation. Your palms are sweaty, your mind racing. How you talk to yourself in that moment can dramatically impact the outcome. Research shows that the words we use internally can influence everything from decision-making to stress levels.
PharmExec
AUGUST 1, 2024
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, identifies Organon's efforts to invest in research, education, and its pipeline to focus on critical areas of need in maternal health.
Pharmaceutical Commerce
AUGUST 1, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, discusses the development of frozen/cold biologics when it comes to the logistics space, along with how the companies themselves have changed over the years.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
269 
Let's personalize your content